title: Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model.
abstract: OBJECTIVE
  To assess the activity of brivaracetam, a novel SV2A ligand, in the photosensitivity model as a proof-of-principle of efficacy in patients with epilepsy.
  
  
  METHODS
  A subject-blind placebo-controlled study in patients with photosensitive epilepsy was performed to investigate the effect of single-dose brivaracetam (10, 20, 40, or 80 mg) on photosensitive responses. Each patient was exposed to intermittent photic stimulation that evoked a generalized photoparoxysmal EEG response. Individual standard photosensitivity ranges (SPRs) were recorded post-placebo (day -1) and post-brivaracetam until return to baseline (day 1 to 3). Plasma concentrations of brivaracetam and any concomitant antiepileptic drugs were determined.
  
  
  RESULTS
  Of the 18 evaluable patients, none achieved SPR abolishment post-placebo, whereas 14 (78%) achieved complete abolishment post-brivaracetam. Decrease in SPR was seen in 8 patients (44%) post-placebo compared to 17 (94%) post-brivaracetam. Duration of response was twice as long post-brivaracetam 80 mg (59.5 hours) compared with lower doses, although the overall effect was not dose-dependent. Time to maximal photosensitive response was dose-related with the shortest time interval observed at the highest dose (0.5 hours post-brivaracetam 80 mg). The area under the effect curve (SPR change from pre-dose vs time) appeared linearly correlated with the area under the plasma concentration curve. Brivaracetam was well tolerated. The most common adverse events were dizziness and somnolence.
  
  
  CONCLUSIONS
  Our findings show that brivaracetam clearly suppresses generalized photoparoxysmal EEG response. As such, investigations of the antiepileptic properties and tolerability of brivaracetam are warranted in further clinical studies of patients with epilepsy.
authors.affiliation: University of Rome, Rome, Italy. Dorothee.Kasteleijn@uniroma1.it
authors.forename: D G A
authors.initials: DG
authors.lastname: Kasteleijn-Nolst Trenité
authors.forename: P
authors.initials: P
authors.lastname: Genton
authors.forename: D
authors.initials: D
authors.lastname: Parain
authors.forename: P
authors.initials: P
authors.lastname: Masnou
authors.forename: B J
authors.initials: BJ
authors.lastname: Steinhoff
authors.forename: T
authors.initials: T
authors.lastname: Jacobs
authors.forename: E
authors.initials: E
authors.lastname: Pigeolet
authors.forename: A
authors.initials: A
authors.lastname: Stockis
authors.forename: E
authors.initials: E
authors.lastname: Hirsch
mesh_terms: D000293:Adolescent; D000328:Adult; D004305:Dose-Response Relationship, Drug; D020195:Epilepsy, Reflex / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008024:Ligands; D008297:Male; D008562:Membrane Glycoproteins / Q000378:metabolism*; D008875:Middle Aged; D009419:Nerve Tissue Proteins / Q000378:metabolism*; D010775:Photic Stimulation / Q000379:methods; D011760:Pyrrolidinones / Q000378:metabolism* / Q000627:therapeutic use*; D016037:Single-Blind Method